Matjaž Homan1,2, Jernej Kovač3, Rok Orel4,5, Tadej Battelino5,6, Primož Kotnik5,6. 1. Department of Gastroenterology, Hepatology and Nutrition, University Children's hospital, University Medical Center Ljubljana, Bohoričeva 20, SI-1000, Ljubljana, Slovenia. matjaz.homan@guest.arnes.si. 2. Department of Pediatrics, Faculty of Medicine, University of Ljubljana, Bohoričeva 20, SI-1000, Ljubljana, Slovenia. matjaz.homan@guest.arnes.si. 3. Unit of Special Laboratory Diagnostics, University Children's Hospital, University Medical Center Ljubljana, Vrazov trg 1, SI-1000, Ljubljana, Slovenia. 4. Department of Gastroenterology, Hepatology and Nutrition, University Children's hospital, University Medical Center Ljubljana, Bohoričeva 20, SI-1000, Ljubljana, Slovenia. 5. Department of Pediatrics, Faculty of Medicine, University of Ljubljana, Bohoričeva 20, SI-1000, Ljubljana, Slovenia. 6. Department of Endocrinology, Diabetes And Metabolism, University Children's Hospital, University Medical Center Ljubljana, Bohoričeva 20, SI-1000, Ljubljana, Slovenia.
Abstract
BACKGROUND: Duodenojejunal bypass liner (DJBL) is an endoscopic, reversible bariatric procedure resulting in weight loss and metabolic co-morbidities improvements in the adults. OBJECTIVES: To determine safety and effectiveness of 12-month treatment with DJBL in adolescents with severe obesity (BMI > 35 kg/m2) and co-morbidities. METHODS: Post-pubertal subjects were treated with DJBL in an open-label, prospective clinical trial (NTC0218393). They were examined at 3 monthly intervals during the 12 months of DJBL treatment and 12 months of follow-up. RESULTS: DJBL was successfully placed in 19/22 adolescents (13 females, mean age (95%CI); 17.3 (16.7-17.9) years, BMI-SDS 3.7 (3.6-3.9)). There were no serious device-related adverse effects. Clinically relevant percent total weight loss (%TWL) (mean (95%CI)) 11.4 (7.4-15.3) % and BMI decrease - 4.9 (- 2.4 to - 7.4) kg/m2 was observed at DJBL removal (n = 19). At 12 months after device removal, %TWL was 4.1 (- 2.6-10.8) % and BMI decrease - 2.6 (0.2 to - 5.4) kg/m2 when compared with values at baseline (n = 13). HOMA-IR (- 2.1 (- 3 to - 1.3), WBISI 1.15 (0.23 to 2.07), total cholesterol, LDL-c, and triglycerides levels also improved during DJBL treatment and relapsed similarly to weight at 12-month follow-up. A decrease in iron stores, Zn, and Se levels was determined during DJBL treatment and spontaneously improved at follow-up. CONCLUSIONS: Twelve months of DJBL treatment was safe and effective in adolescents with morbid obesity. Weight regain following device removal and relapse of metabolic complications should be expected.
BACKGROUND: Duodenojejunal bypass liner (DJBL) is an endoscopic, reversible bariatric procedure resulting in weight loss and metabolic co-morbidities improvements in the adults. OBJECTIVES: To determine safety and effectiveness of 12-month treatment with DJBL in adolescents with severe obesity (BMI > 35 kg/m2) and co-morbidities. METHODS: Post-pubertal subjects were treated with DJBL in an open-label, prospective clinical trial (NTC0218393). They were examined at 3 monthly intervals during the 12 months of DJBL treatment and 12 months of follow-up. RESULTS: DJBL was successfully placed in 19/22 adolescents (13 females, mean age (95%CI); 17.3 (16.7-17.9) years, BMI-SDS 3.7 (3.6-3.9)). There were no serious device-related adverse effects. Clinically relevant percent total weight loss (%TWL) (mean (95%CI)) 11.4 (7.4-15.3) % and BMI decrease - 4.9 (- 2.4 to - 7.4) kg/m2 was observed at DJBL removal (n = 19). At 12 months after device removal, %TWL was 4.1 (- 2.6-10.8) % and BMI decrease - 2.6 (0.2 to - 5.4) kg/m2 when compared with values at baseline (n = 13). HOMA-IR (- 2.1 (- 3 to - 1.3), WBISI 1.15 (0.23 to 2.07), total cholesterol, LDL-c, and triglycerides levels also improved during DJBL treatment and relapsed similarly to weight at 12-month follow-up. A decrease in iron stores, Zn, and Se levels was determined during DJBL treatment and spontaneously improved at follow-up. CONCLUSIONS: Twelve months of DJBL treatment was safe and effective in adolescents with morbid obesity. Weight regain following device removal and relapse of metabolic complications should be expected.
Authors: Shelby Sullivan; Nitin Kumar; Steven A Edmundowicz; Barham K Abu Dayyeh; Sreenivasa S Jonnalagadda; Michael Larsen; Christopher C Thompson Journal: Gastrointest Endosc Date: 2015-08-15 Impact factor: 9.427
Authors: Justin R Ryder; Alexander M Kaizer; Todd M Jenkins; Aaron S Kelly; Thomas H Inge; Gabriel Q Shaibi Journal: Obesity (Silver Spring) Date: 2019-02 Impact factor: 5.002
Authors: Thomas H Inge; Anita P Courcoulas; Todd M Jenkins; Marc P Michalsky; Mary L Brandt; Stavra A Xanthakos; John B Dixon; Carroll M Harmon; Mike K Chen; Changchun Xie; Mary E Evans; Michael A Helmrath Journal: N Engl J Med Date: 2019-05-16 Impact factor: 91.245
Authors: Markus Juonala; Costan G Magnussen; Gerald S Berenson; Alison Venn; Trudy L Burns; Matthew A Sabin; Sathanur R Srinivasan; Stephen R Daniels; Patricia H Davis; Wei Chen; Cong Sun; Michael Cheung; Jorma S A Viikari; Terence Dwyer; Olli T Raitakari Journal: N Engl J Med Date: 2011-11-17 Impact factor: 91.245
Authors: Thomas H Inge; Anita P Courcoulas; Todd M Jenkins; Marc P Michalsky; Michael A Helmrath; Mary L Brandt; Carroll M Harmon; Meg H Zeller; Mike K Chen; Stavra A Xanthakos; Mary Horlick; C Ralph Buncher Journal: N Engl J Med Date: 2015-11-06 Impact factor: 91.245
Authors: Torsten Olbers; Andrew J Beamish; Eva Gronowitz; Carl-Erik Flodmark; Jovanna Dahlgren; Gustaf Bruze; Kerstin Ekbom; Peter Friberg; Gunnar Göthberg; Kajsa Järvholm; Jan Karlsson; Staffan Mårild; Martin Neovius; Markku Peltonen; Claude Marcus Journal: Lancet Diabetes Endocrinol Date: 2017-01-06 Impact factor: 32.069
Authors: B Betzel; M I Cooiman; E O Aarts; I M C Janssen; P J Wahab; M J M Groenen; J P H Drenth; F J Berends Journal: Surg Endosc Date: 2019-03-14 Impact factor: 4.584